Skip to main content
HCV patients with kidney disease respond to combo drug

A New Zealand study found the combination of glecaprevir, an NS3/4A protease inhibitor, and Mavyret, or pibrentasvir, an NS5A inhibitor, safe and effective in patients with chronic kidney disease and hepatitis C. Sustained virologic response was seen in 98% of patients, according to findings in The New England Journal of Medicine.

Full Story: